Central Nervous System Therapeutic Market: By Disease Type (Neurovascular Diseases, Trauma, Mental Health, Degenerative Disease, Infectious Diseases, Cancer, and Others), By Drug Class (Analgesics, Antidepressants, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

Central Nervous System Therapeutics Market was valued at USD 133.8 billion in 2023 and is expected to grow at a 7.41% CAGR from 2024 to 2030. The central nervous system is a vital part of the nervous system that consists of the brain and spinal cord. The CNS integrates the received information and, thereafter, coordinates and controls the activities of all parts of the body. The CNS disorders like autoimmune & inflammatory diseases, genetic disorders, neurodegenerative diseases, and others affect the structure and function of the brain and the spinal cord. The increasing prevalence of mental illness and lifestyle associated with CNS disorders and a growing number of geriatric populations are expected to majorly drive the growth of the central nervous system therapeutics market over the forecast period. For instance, the rate of serious psychological distress among adolescents and young adults has been on the rise for the past few years, which is further expected to fuel the demand for CNS therapeutics across the globe. In addition, advancements in diagnostics, therapeutics, and drug discovery techniques are expected to further propel the growth of the central nervous system market over the forecast period.

Furthermore, the growing number of awareness programs about CNS disorders and their therapeutics by regulatory bodies in several developing countries across the globe is expected to have a positive impact on market growth. For instance, The World Health Organization and the American Association of Neurological Surgeons conduct various seminars to increase awareness about psychological disorders and their treatments. However, factors such as the high cost of advanced treatments, along with stringent and prolonged drug approvals by the regulatory bodies are expected to hinder the growth of the central nervous system therapeutics market over the forecast period. Moreover, the increasing demand for effective CNS therapy options encourages the market players and pharmaceutical companies to invest in research and development, thus creating growth opportunities in the CNS therapeutic market over the forecast period.

Central Nervous System Therapeutics Market Key Developments:

• In June 2022, USFDA approved CNS Pharmaceuticals Inc. ongoing potentially pivotal global study evaluating the efficacy and safety of Berubicin.